Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cadrenal Therapeutics, Inc.CVKD · Entity 8251 | Director · Chairman and CEO · 10% owner | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cadrenal Therapeutics, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2036-10-08 | Direct | 200,000 |
Reported balance
After 2026-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 200,000 · Balance 200,000 F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 21:33 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001213900-26-109132 · ownership.xml · derivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chairman and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-10-08 F1 · shares: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. F1 · derivative.exercise_date: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 01:52 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 7,400 | $3.03 | $22,422.00 |
DisclosureSEC source: 0001213900-26-074557 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,589 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 26, 2026 Filed Jun 27, 2026 00:44 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 9,029 | $3.05 | $27,538.45 |
DisclosureSEC source: 0001213900-26-072789 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,989 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2026 Filed Jun 27, 2026 00:44 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 2,127 | $3.00 | $6,381.00 |
DisclosureSEC source: 0001213900-26-072789 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,018 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 21:15 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 2,277 | $3.20 | $7,286.40 |
DisclosureSEC source: 0001213900-26-071578 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,145 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 through $3.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:15 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 9,167 | $3.55 | $32,542.85 |
DisclosureSEC source: 0001213900-26-071578 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,422 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 through $3.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 22:36 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 513 | $3.16 | $1,621.08 |
DisclosureSEC source: 0001213900-26-070248 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,589 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.14 through $3.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 22:36 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 3,613 | $3.18 | $11,489.34 |
DisclosureSEC source: 0001213900-26-070248 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,102 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.04 through $3.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 00:58 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 3,666 | $3.58 | $13,124.28 |
DisclosureSEC source: 0001213900-26-068981 · ownership.xml · nonDerivative · entry 3 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,715 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.22 through $3.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 00:58 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 12,996 | $3.94 | $51,204.24 |
DisclosureSEC source: 0001213900-26-068981 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,381 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 through $4.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 00:58 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,462 | $4.12 | $6,023.44 |
DisclosureSEC source: 0001213900-26-068981 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,377 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.09 through $4.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 00:26 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 3,500 | $4.21 | $14,735.00 |
DisclosureSEC source: 0001213900-26-067484 · ownership.xml · nonDerivative · entry 3 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,839 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.20 through $4.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 00:26 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 12,992 | $4.06 | $52,747.52 |
DisclosureSEC source: 0001213900-26-067484 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,339 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 through $4.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 00:26 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 5,893 | $4.38 | $25,811.34 |
DisclosureSEC source: 0001213900-26-067484 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chairman, CEO and Interim CFO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,331 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.20 through $4.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:26 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 2,064 | $4.42 | $9,122.88 |
DisclosureSEC source: 0001213900-26-065925 · ownership.xml · nonDerivative · entry 3 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,224 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.25 through $4.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 21:26 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 3,898 | $4.41 | $17,190.18 |
DisclosureSEC source: 0001213900-26-065925 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,288 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 through $4.47. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:26 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 2,323 | $4.26 | $9,895.98 |
DisclosureSEC source: 0001213900-26-065925 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,186 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 through $4.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 00:34 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 349 | $4.46 | $1,556.54 |
DisclosureSEC source: 0001213900-26-064357 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,509 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 through $4.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:34 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 303 | $5.01 | $1,518.03 |
DisclosureSEC source: 0001213900-26-064357 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,858 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 through $5.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:30 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 2,989 | $4.93 | $14,735.77 |
DisclosureSEC source: 0001213900-26-062862 · ownership.xml · nonDerivative · entry 3 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,161 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 through $5.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 22, 2026 Filed May 27, 2026 01:06 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,165 | $5.69 | $6,628.85 |
DisclosureSEC source: 0001213900-26-061167 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,924 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.60 through $5.82. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2026 Filed May 29, 2026 20:30 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 3,298 | $5.28 | $17,413.44 |
DisclosureSEC source: 0001213900-26-062862 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,150 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 through $5.535. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The total shares reported as directly owned in Column 5 takes into account subsequent transactions effected by the Reporting Person and reported on a Form 4 filed on May 26, 2026. Read SEC document |
| May 11, 2026 Filed May 29, 2026 20:30 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 6,476 | $5.76 | $37,301.76 |
DisclosureSEC source: 0001213900-26-062862 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,448 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.47 through $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The total shares reported as directly owned in Column 5 takes into account subsequent transactions effected by the Reporting Person and reported on a Form 4 filed on May 26, 2026. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 21:00 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,315 | $13.99 | $18,396.85 |
DisclosureSEC source: 0001213900-25-103146 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,089 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 21:00 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,129 | $14.03 | $15,839.87 |
DisclosureSEC source: 0001213900-25-103146 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,404 F1 · shares: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.10. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 20:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,800 | $14.15 | $25,470.00 |
DisclosureSEC source: 0001213900-25-098719 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,533 F2 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.33, inclusive, having a weighted average price as shown in column 4 of $14.15. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 20:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,800 | $14.02 | $25,236.00 |
DisclosureSEC source: 0001213900-25-098719 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,333 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.11, inclusive, having a weighted average price as shown in column 4 of $14.02. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 02, 2025 Filed Oct 4, 2025 00:24 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 500 | $14.13 | $7,065.00 |
DisclosureSEC source: 0001213900-25-096241 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,133 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $14.04 through $14.27, inclusive, having a weighted average price as shown in column 4 of $14.13. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 21:46 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 881 | $14.01 | $12,342.81 |
DisclosureSEC source: 0001213900-25-094803 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,633 F2 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.05, inclusive, having a weighted average price as shown in column 4 of $14.01. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 21:46 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 419 | $14.01 | $5,870.19 |
DisclosureSEC source: 0001213900-25-094803 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,514 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.02, inclusive, having a weighted average price as shown in column 4 of $14.01. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 25, 2025 Filed Sep 27, 2025 00:35 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 6,790 | $14.09 | $95,671.10 |
DisclosureSEC source: 0001213900-25-092557 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,933 F2 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.14, inclusive, having a weighted average price as shown in column 4 of $14.09. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 24, 2025 Filed Sep 27, 2025 00:35 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 2,581 | $13.99 | $36,108.19 |
DisclosureSEC source: 0001213900-25-092557 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,723 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions, at a price of $13.99 for each transaction. Read SEC document |
| August 28, 2025 Filed Aug 30, 2025 00:34 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,193 | $13.99 | $16,690.07 |
DisclosureSEC source: 0001213900-25-082819 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,304 F2 · price: Represents shares of the Issuer's common stock sold on the Transaction Date by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.04, inclusive, having a weighted average price as shown in column 4 of $13.99. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 27, 2025 Filed Aug 30, 2025 00:34 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 3,836 | $13.99 | $53,665.64 |
DisclosureSEC source: 0001213900-25-082819 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,497 F1 · price: Represents shares of the Issuer's common stock sold on the Transaction Date by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.03, inclusive, having a weighted average price as shown in column 4 of $13.99. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 23:10 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 65,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001213900-25-006630 · ownership.xml · derivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-01-22 F1 · security: Consists of options to purchase 65,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to 110% of the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| January 23, 2025 Filed Mar 25, 2025 00:38 UTC Amendment | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 65,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001013762-25-001779 · ownership.xml · derivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-01-22 F1 · security: This amendment to Form 4 is being filed to correct the exercise price and the expiration date of the stock option, which were incorrectly reported on the original Form 4 filed by the Reporting Person on January 24, 2025 (the "Original Form 4"). The exercise price of the stock option is equal to 100% of the fair market value of the Issuer's common stock on the effective date of the grant and the stock option expires ten years from the date of issuance. The stock option vests according to the vesting schedule as previously reported on the Original Form 4. Read SEC document |
| April 10, 2024 Filed Apr 10, 2024 21:30 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-031923 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,275,000 F1 · shares: On April 10, 2024 Quang Pham transferred an aggregate of 50,000 shares of common stock to a non-for-profit organization, as a gift for no value received, pursuant to a written agreement with the organizations signed by a representative of such organization and Mr. Pham. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 00:40 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-005001 · ownership.xml · derivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-01-17 F1 · security: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. F1 · derivative.exercise_date: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. Read SEC document |
| October 23, 2023 Filed Feb 13, 2024 02:41 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GiftCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-012837 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,325,000 F1 · shares: On October 23, 2023, Quang Pham transferred an aggregate of 85,000 shares of common stock to three non-for-profit organizations, as gifts for no value received, pursuant to a written agreement with each of the three organizations signed by a representative of each such organization and Mr. Pham. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 19:28 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | PurchaseCommon Stock | 20,000 | $0.90 | $17,988.00 |
DisclosureSEC source: 0001213900-23-074336 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,410,000 Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 19:28 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | PurchaseCommon Stock | 20,000 | $0.91 | $18,200.00 |
DisclosureSEC source: 0001213900-23-074336 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,390,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | PurchaseCommon Stock | 10,000 | $0.84 | $8,433.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 5 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,370,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | PurchaseCommon Stock | 10,000 | $0.92 | $9,168.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 4 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,360,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | PurchaseCommon Stock | 20,000 | $0.92 | $18,444.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 3 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | PurchaseCommon Stock | 20,000 | $0.93 | $18,582.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,330,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | PurchaseCommon Stock | 10,000 | $0.93 | $9,318.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,310,000 Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 14:00 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantCommon Stock | 25,000 | $1.94 | $48,500.00 |
DisclosureSEC source: 0001213900-23-010504 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.